No Data
No Data
Capital One Financial Maintains GlycoMimetics(GLYC.US) With Hold Rating, Maintains Target Price $0.5
Capital One Financial analyst Naureen Quibria maintains $GlycoMimetics(GLYC.US)$ with a hold rating, and maintains the target price at $0.5.According to TipRanks data, the analyst has a success rate o
HC Wainwright & Co. Reiterates Neutral on GlycoMimetics
HC Wainwright & Co. analyst Edward White reiterates GlycoMimetics (NASDAQ:GLYC) with a Neutral.
H.C. Wainwright Maintains GlycoMimetics(GLYC.US) With Hold Rating
H.C. Wainwright analyst Edward White maintains $GlycoMimetics(GLYC.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 30.5% and a total average return of -14.2% over
Express News | GlycoMimetics Shares Are Trading Higher After the Company Announced Results From Its Phase 3 Study of Uproleselan in R/R AML Demonstrating a Clinically Meaningful Improvement in Median Overall Survival
Express News | GlycoMimetics-Advancing Discussion With Nci,Alliance for Clinical Trials in Oncology Based on Results of Pivotal Phase 3 Study of Uproleselan in R/R Aml
Express News | GlycoMimetics Announces Comprehensive Results From Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml)
No Data